Article révisé par les pairs
Titre:
  • Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
Auteur:Cardoso, Fatima; Durbecq, Virginie; Laes, Jean-François; Badran, Bassam; Lagneaux, Laurence; Bex, Françoise; Desmedt, Christine; Willard-Gallo, Karen; Ross, Jeffrey S.; Burny, Arsène; Piccart-Gebhart, Martine; Sotiriou, Christos
Informations sur la publication:Molecular cancer therapeutics, 5, 12, page (3042-3051)
Statut de publication:Publié, 2006-12
Sujet CREF:Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
MeSH keywords:Antibodies, Monoclonal -- administration & dosage
Antibodies, Monoclonal -- pharmacology
Antineoplastic Combined Chemotherapy Protocols -- pharmacology
Apoptosis -- drug effects
Boronic Acids -- administration & dosage
Boronic Acids -- pharmacology
Breast Neoplasms -- drug therapy
Breast Neoplasms -- enzymology
Breast Neoplasms -- metabolism
Breast Neoplasms -- pathology
Cell Line, Tumor
Cell Nucleus -- metabolism
Cyclin-Dependent Kinase Inhibitor p27 -- metabolism
Drug Resistance, Neoplasm
Drug Synergism
Humans
NF-kappa B -- biosynthesis
NF-kappa B -- metabolism
Pyrazines -- administration & dosage
Pyrazines -- pharmacology
Receptor, erbB-2 -- biosynthesis
Note générale:Journal Article
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:1535-7163
info:doi/10.1158/1535-7163.MCT-06-0104
info:pii/1535-7163.MCT-06-0104
info:scp/33846216907
info:pmid/17148762

Documents en relation

DI-fusion